Protherics PLC Notification of Director's Interests London, UK; Brentwood, TN; 1 October 2007 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today announces that, on 28 September 2007, in accordance with paragraph 3.1.2 of the FSA Disclosure and Transparency Rules, the Company received notification that, on 28 September 2007, Garry Watts, Non-executive Director of Protherics, acquired 40,000 ordinary 2p shares in the Company (" Ordinary Shares") at a price of 48.42 pence per share. Following the above transaction, Mr. Watts holds a beneficial interest in 90,000 Ordinary Shares (0.026% of the issued ordinary share capital of the Company). The Company's issued ordinary share capital is 339,316,822 shares. | Ends | For further information please contact: Protherics Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510 Julie Vickers, Company Secretary +44 (0)1928 518010 Financial Dynamics - press enquiries London: Ben Atwell, David Yates +44 (0) 20 7831 3113 New York: John Capodanno, Jonathan Birt +1 212 850 5600 Or visit www.protherics.com This information is provided by RNS The company news service from the London Stock Exchange END
Protherics PLC announces Director Dealings
| Source: Protherics PLC
Cheshire, UK--(Marketwire - October 1, 2007) -